Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 86

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 86
---
 paid-in capital21,333 20,180 Accumulated deficit(7,900)(1,000)Accumulated other comprehensive loss(1,925)(2,305)Total stockholders' equity3,325 10,360 Noncontrolling interest39 37 Total equity3,364 10,397 Total liabilities and equity$135,161 $134,711 

The accompanying notes are an integral part of these consolidated financial statements.

53     |  2024 Form 10-K

AbbVie Inc. and Subsidiaries

Consolidated Statements of Equity

years ended December 31 (in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capital Retained earnings (accumulated deficit)Accumulated other comprehensive lossNoncontrolling interestTotalBalance at December 31, 20211,768 $18 $(3,143)$18,305 $3,127 $(2,899)$28 $15,436 Net earnings attributable to AbbVie Inc.— — — — 11,836 — — 11,836 Other comprehensive income, net of tax— — — — — 700 — 700 Dividends declared— — — — (10,179)— — (10,179)Purchases of treasury stock(10)— (1,487)— — — — (1,487)Stock-based compensation plans and other11 — 36 940 — — — 976 Change in noncontrolling interest— — — — — — 5 5 Balance at December 31, 20221,769 18 (4,594)19,245 4,784 (2,199)33 17,287 Net earnings attributable to AbbVie Inc.— — — — 4,863 — — 4,863 Other comprehensive loss, net of tax— — — — — (106)— (106)Dividends declared— — — — (10,647)— — (10,647)Purchases of treasury stock(12)— (1,978)— — — — (1,978)Stock-based compensation plans and other9 — 39 935